4565 Nxera Pharma Co.,Ltd.ネクセラファーマTSE Prime / Pharmaceuticals
0 posts
Nxera Pharma Co.,Ltd. (4565) at a glance
Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.
Nxera Pharma Co.,Ltd. (4565) Stock Price History
Nxera Pharma Co.,Ltd. closed at ¥1,600 on Nov 20, 2026, +33.8% over 1 month, +86.9% over 1 year.
If you had invested ¥100,000 1 month ago, it would be worth ¥133,779 today (+33.8%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −11.9%, while this stock moved +33.8%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥1,600 | −64 | −3.85% |
| Nov 19 (Thu) | ¥1,664 | −44 | −2.58% |
| Nov 18 (Wed) | ¥1,708 | −37 | −2.12% |
| Nov 17 (Tue) | ¥1,745 | −62 | −3.43% |
| Nov 16 (Mon) | ¥1,807 | −6 | −0.33% |
| Nov 13 (Fri) | ¥1,813 | +25 | +1.40% |
| Nov 12 (Thu) | ¥1,788 | −23 | −1.27% |
| Nov 11 (Wed) | ¥1,811 | +15 | +0.84% |
| Nov 10 (Tue) | ¥1,796 | +92 | +5.40% |
| Nov 9 (Mon) | ¥1,704 | +117 | +7.37% |
If you had invested ¥100,000 3 months ago, it would be worth ¥141,218 today (+41.2%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −14.8%, while this stock moved +41.2%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥1,600 | −64 | −3.85% |
| Nov 19 (Thu) | ¥1,664 | −44 | −2.58% |
| Nov 18 (Wed) | ¥1,708 | −37 | −2.12% |
| Nov 17 (Tue) | ¥1,745 | −62 | −3.43% |
| Nov 16 (Mon) | ¥1,807 | −6 | −0.33% |
| Nov 13 (Fri) | ¥1,813 | +25 | +1.40% |
| Nov 12 (Thu) | ¥1,788 | −23 | −1.27% |
| Nov 11 (Wed) | ¥1,811 | +15 | +0.84% |
| Nov 10 (Tue) | ¥1,796 | +92 | +5.40% |
| Nov 9 (Mon) | ¥1,704 | +117 | +7.37% |
If you had invested ¥100,000 6 months ago, it would be worth ¥144,404 today (+44.4%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −5.6%, while this stock moved +44.4%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥1,600 | +11.1% |
| Oct 2026 | ¥1,440 | +15.3% |
| Sep 2026 | ¥1,249 | +9.9% |
| Aug 2026 | ¥1,136 | +29.7% |
| Jul 2026 | ¥876 | −11.5% |
| Jun 2026 | ¥990 | −7.2% |
| May 2026 | ¥1,067 | +9.9% |
If you had invested ¥100,000 1 year ago, it would be worth ¥186,916 today (+86.9%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +13.3%, while this stock moved +86.9%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥1,600 | +11.1% |
| Oct 2026 | ¥1,440 | +15.3% |
| Sep 2026 | ¥1,249 | +9.9% |
| Aug 2026 | ¥1,136 | +29.7% |
| Jul 2026 | ¥876 | −11.5% |
| Jun 2026 | ¥990 | −7.2% |
| May 2026 | ¥1,067 | +9.9% |
| Apr 2026 | ¥971 | +11.4% |
| Mar 2026 | ¥872 | −9.7% |
| Feb 2026 | ¥966 | +19.0% |
| Jan 2026 | ¥812 | −1.8% |
| Dec 2025 | ¥827 | −6.8% |
| Nov 2025 | ¥887 | ― |
If you had invested ¥100,000 3 years ago, it would be worth ¥110,193 today (+10.2%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +67.8%, while this stock moved +10.2%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥1,600 | +93.5% |
| 2025 | ¥827 | ― |
If you had invested ¥100,000 5 years ago, it would be worth ¥71,685 today (−28.3%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +96.3%, while this stock moved −28.3%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥1,600 | +93.5% |
| 2025 | ¥827 | ― |
If you had invested ¥100,000 in Aug 2004, it would be worth ¥111,111 today (+11.1%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +421.4%, while this stock moved +11.1%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥1,600 | +93.5% |
| 2025 | ¥827 | −21.1% |
| 2024 | ¥1,048 | −26.2% |
| 2023 | ¥1,421 | −33.5% |
| 2022 | ¥2,138 | +12.3% |
| 2021 | ¥1,904 | +5.8% |
| 2020 | ¥1,800 | −17.1% |
| 2019 | ¥2,171 | +171.7% |
| 2018 | ¥799 | −70.8% |
| 2017 | ¥2,735 | −18.7% |
| 2016 | ¥3,363 | +35.2% |
| 2015 | ¥2,488 | +127.7% |
| 2014 | ¥1,093 | +1.3% |
| 2013 | ¥1,079 | +106.8% |
| 2012 | ¥522 | +64.2% |
| 2011 | ¥318 | −5.9% |
| 2010 | ¥338 | +29.1% |
| 2009 | ¥262 | +240.2% |
| 2008 | ¥76.9 | −80.2% |
| 2007 | ¥388 | −32.6% |
| 2006 | ¥575 | −47.0% |
| 2005 | ¥1,085 | −24.5% |
| 2004 | ¥1,438 | ― |
Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Aug 2004). Please check the latest prices before trading.
Nxera Pharma Co.,Ltd. (4565) financial indicators
PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.
Key features of Nxera Pharma Co.,Ltd. (4565)
Business overview
As a technology-based biopharmaceutical company, it aims to meet unmet needs in Japan and around the world and deliver new specialty medicines that improve patients' quality of life. Its core business spans drug research (discovery) to development and sales, and it has a single pharmaceutical segment. Drug discovery, translational medicine and preclinical and early clinical development are handled mainly by UK-based subsidiary Nxera Pharma UK Limited, and clinical development and sales in Japan and South Korea mainly by 「ネクセラファーマジャパン」 in Japan and Nxera Pharma Korea Co., Ltd. in South Korea, with future expansion into the rest of Asia-Pacific excluding China in view. The UK subsidiary conducts GPCR structural analysis and searches for candidates using its proprietary NxStaR technology.
Summarized from the annual securities report (fiscal year ended December 2025) filed on EDINET.
Position within Pharmaceuticals (79 companies)
| PBR | 2.28x | Above the sector median of 1.86x (No. 47 from the lowest) |
|---|---|---|
| Market cap | ¥146.2 bn | No. 19 in the sector (largest first) |
Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.
Price milestones
| 52-week high | ¥1,813 | 11/13 |
|---|---|---|
| 52-week low | ¥754 | 2025/12/19 |
| Current position | 79.9% | Where the low is 0% and the high is 100% (close on 11/20: ¥1,600) |
| Year to date | +93.5% | No. 2 of 77 in the sector (best first) |
| 1 year | +86.9% |
Based on closing prices (adjusted for stock splits, excluding dividends).
Kabutaro's ranking history
| Top 50 gainers | 3 times | Latest: 11/5 (No. 9) |
|---|
Gainers and losers have been recorded since 9/2026.
Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.
Recent disclosures (TDnet, in Japanese)
- 11/04 15:302026年12月期業績予想の修正に関するお知らせ
- 11/04 15:30炎症性腸疾患を対象とした新規EP4受容体作動薬NXE0033744について、AbbVieとグローバルライセンス契約を締結
- 10/30 15:302026年12月期第3四半期決算短信〔IFRS〕(連結)
- 10/30 15:302026年12月期第3四半期累計期間(1月-9月)ビジネスハイライトおよび連結業績について
- 10/28 16:00ファブリー病治療薬候補lucerastatの日本およびアジア太平洋の一部地域における独占的ライセンス契約締結のお知らせ
- 10/22 15:30デュシェンヌ型筋ジストロフィー治療薬vamoroloneの韓国における製造販売承認申請のお知らせ
- 10/20 17:00今後の執行役向けRSU付与の見直しならびに執行役向け業績連動型ストックオプションプランの導入および同プランに基づく新株予約権の発行に関するお知らせ
- 10/14 16:00不眠症治療薬 ダリドレキサントに関してSynmosa社とアジア太平洋8カ国における独占的ライセンス契約締結
Filings from the past 12 months (8).
Posts
This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.
No posts yet. Be the first to write something.
Write on the Nxera Pharma Co.,Ltd. board
More Japanese stocks in English
- KYORIN Pharmaceutical Co.,Ltd.4569
- HUMAN MADE Inc.456A
- Immuno-Biological Laboratories Co.,Ltd.4570
- Nano Holdings,Inc.4571
- Carna Biosciences,Inc.4572
- TAIKO PHARMACEUTICAL CO.,LTD.4574
- CanBas Co.,Ltd.4575
- D.Western Therapeutics Institute, Inc.4576
- Daito Pharmaceutical Co.,Ltd.4577
- RaQualia Pharma Inc.4579
- Le Lien Co.,Ltd.457A
- SymBio Pharmaceuticals Limited4582